[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-2,3,4-trihydroxy-5-(6-hydroxy-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)pentyl] hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 黄素核苷酸
• 英文名称: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-2,3,4-trihydroxy-5-(6-hydroxy-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)pentyl] hydrogen phosphate
• 化学式: C₂₇H₃₃N₉O₁₆P₂
• 分子量: 801.5
• InChiKey: BJSUUWFQAMLNKU-OKXKTURISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.3
• 重原子数：
  54
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  377
• 氢给体数：
  10
• 氢受体数：
  21

文献信息

• Appetite suppressant compositions and methods thereof
  申请人：Red Mountain Holdings, LLC

  公开号：US11344556B2

  公开（公告）日：2022-05-31

  In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

  在各种实施方案中，食欲抑制剂组合物包括至少一种厌食症活性成分（AAI）；营养物质、控制给药剂（CDRA）和辅助因子中的至少一种；以及可选的赋形剂。AIA可包括芬特明、芬地美曲秦、地特丙酮、纳曲酮和安非他酮中的任意一种。CDRA 可包括纤维素。辅助因子可包括铬盐或硒盐。在各种实施方案中，本文中的组合物以口服胶囊剂型提供，用于胃肠道给药 AAI。描述了一种抑制需要者食欲的方法。
• APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF
  申请人：Red Mountain Holdings, LLC

  公开号：US20210275536A1

  公开（公告）日：2021-09-09

  In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.